Topical 5‐fluorouracil in the treatment of vaginal intraepithelial neoplasia

Abstract

T h e effectiveness ot in the treatment of vaginal intraepithelial neoplasia was assessed in 14 patients diagnosed with t h e condition between January 1980 a n d December 1982. All patients received a standard dose of 2.5 g 5-fluorouracil cream once weekly f o r at least 10 consecutive weeks: m e a n duration of treatment w a s 12 weeks (range 10-20 weeks). T h e vaginal lesion was associated with a major dysplastic lesion of t h e cervix in all patients. The duration of follow-up ranged f r o m 4 t o 42 m o n t h s ( m e a n 15 months). Thirteen patients h a d complete resolution both colposcopically and cytologically. One patient still h a d colposcopic evidence of intraepithelial neoplasia (aceto-white epithelium) b u t a vaginal s m e a r h a s been negative. This patient has since been lost t o follow-up. We conclude that in t h e regimen described 5-fluorouracil is an effective treatment f o r vaginal intra-

Management of Vaginal Intraepithelial Neoplasia

“…It does not seem to affect sexual function. The dosage used is 2 g once weekly for 10 to 12 weeks [38,39].…”

A Paclitaxel‐Based Mucoadhesive Nanogel with Multivalent Interactions for Cervical Cancer Therapy

“…Recently, a great quantity of vaginal formulations comprising of gels, tablets, films, patches, pessaries, and vaginal rings have been reported . However, only a fraction of them have been investigated for the treatment of cervical cancer . It is mainly because the efficacy of all these formulations cannot satisfy the patients' demand for treatment on account of the following disadvantages.…”

Disulfiram-loaded immediate and extended release vaginal tablets for the localised treatment of cervical cancer

“…The vagina has been used to deliver drugs for a range of clinical and research applications, including contraception, vaginal infections and HIV prevention, with many different vaginal formulations such as gels, creams, pessaries, suppositories rings, films and tablets available [10–18]. However, only a small number of these delivery systems have been investigated for the localised delivery of chemotherapeutic drugs to the cervix [19–23]. The vaginal tablet is a very common dosage form that is easy to manufacture, easy to place in the vagina and has a low cost of manufacture, making them ideal for use in developing countries.…”